[go: up one dir, main page]

AR054282A1 - Derivados de tetrahidroquinolina - Google Patents

Derivados de tetrahidroquinolina

Info

Publication number
AR054282A1
AR054282A1 AR20060102411A ARP060102411A AR054282A1 AR 054282 A1 AR054282 A1 AR 054282A1 AR 20060102411 A AR20060102411 A AR 20060102411A AR P060102411 A ARP060102411 A AR P060102411A AR 054282 A1 AR054282 A1 AR 054282A1
Authority
AR
Argentina
Prior art keywords
nnr2
naryl
nheteroaryl
nxr
halogen
Prior art date
Application number
AR20060102411A
Other languages
English (en)
Inventor
Wolfgang Staehle
Kai Schiemann
Dirk Finsinger
Hans-Peter Buchstaller
Frank Zenke
Christiane Amendt
David Bruge
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR054282A1 publication Critical patent/AR054282A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de la formula (1), donde: W representa CH o N; R1, R2, R3, independiente uno del otro, representan H, A, arilo, heteroarilo, halogeno, -(CY2)n-SA, -(CY2)n-SCF3, -(CY2)n-SCN, -(CY2)n-CF3, -(CY2)n-OCF3, cicloalquilo, -SCH3, -SCN, -CF3, - OCF3, -OA, -(CY2)n-OH, -(CY2)n-CO2R, -(CY2)n-CN, -(CY2)n-halogeno, -(CY2)n-NR2, (CY2)n-OA, (CY2)n-OCOA, -SCF3, (CY2)n-CONR2, -(CY2)n-NHCOA, -(CY2)n-NHSO2A, SF5, Si(CH3)3, CO-(CY2)nCH3, -(CY2)n-N-pirolidona, CH(CH2)nNRCOOR, CHNRCOOR, NCO, CH(CH2)nCOOR, NCOOR, CH(CH2)nOH, N(CH2)nOH, CHNH2, CH(CH2)nNR2, CH(CH2)nNR2, C(OH)R, CHNCOR, CH(CH2)narilo, CH(CH2)nheteroarilo, CH(CH2)nR1, N(CH2)nCOOR, CH(CH2)nX(CH2)narilo, CH(CH2)nX(CH2)nheteroarilo, N(CH2)nCONR2, XCONR(CH2)nNR2, N[(CH2)nXCOOR]CO(CH2)narilo, N[(CH2)nXR]CO(CH2)narilo, N[(CH2)nXR]CO(CH2)nXarilo, N[(CH2)nXR]SO2(CH2)narilo, N[(CH2)nNRCOOR]CO(CH2)narilo, N[(CH2)nNR2]CO(CH2)narilo, N[(CH2)nNR2]CO(CH2)nNRarilo, N[(CH2)nNR2]SO2(CH2)narilo, N[(CH2)nXR]CO(CH2)nheteroarilo, N[(CH2)nXR]CO(CH2)nXheteroarilo, N[(CH2)nXR]SO2(CH2)nheteroarilo, N[(CH2)nNRCOOR]CO(CH2)nheteroarilo, N[(CH2)nNR2]CO(CH2)nheteroarilo, N[(CH2)nNR2]CO(CH2)nNRheteroarilo, o R1 y R3 también juntos -N-C(CF3)=N-, -N-CR=N- o -N-N=N- y/o R2 y R3 también representan juntos -N-C(CF3)=N-, -N-CR=N- o -N-N=N-, Y es H, A, halogeno; A representa alquilo o cicloalquilo; donde uno o más átomos de H pueden estar reemplazados por halogeno; halogeno representa F, Cl, Br o I; R representa H o A, con los radicales R terminales también representan juntos -(CH2)5-, -(CH2)4- o -(CH2)n-X-(CH2)n, o -(CH2)2-Z-(CH2)n; U representa [CR4R4']k-[CR8R8'-CR5R5']1-[CR12R12']p, [CR4R4']k-[CR8=CR5]1[CR12R12']p, [CR4R4'-CR8=CR5]k- [CR12R12']p, [CR4R4']k-[CR8=CR5-CR12R12']1 o [CR4R4']k-[CR8R8'-CR5R5']1, R4, R4', R5, R5', R8, R8', R12, R12', independientemente uno del otro, representan H o n-pirolidona, -X(CH2)2OR, -X-CO(CH2)nCH3, -X-(CH2)2NR2, R1, Sarilo, Oarilo, NR2, Q, CN, CH2NR2, (CH2)nNHCONH(CH2)nXR, (CH2)nNHCONH(CH2)nXCOR, (CH2)nNHSO2(CH2)nXR, (CH2)nNHSO2(CH2)nXCOR, NHSO2(CH2)3NMe2, NHCONH(CH2)2NMe2, CH2Si(CH3)3, Ra, Q, -(CY2)n-E-CR2R1, -(CY2)n-E-CR2XR1, -(CY2)n-E-(CY2)n-XR1, -(CY2)n-E-(CY2)n-XRa, no sustituido o sustituido con uno o más grupos OR, NO2, halogeno, CF3, OCF3, CN, NR2 o SR, arilo o heteroarilo, donde R4 y R8 o R5 y R8 también representan juntos -O-, o pueden conformar un enlace, y donde R4, R4' pueden representar O, R5, R5' pueden representar juntos O, R8, R8' pueden representar juntos O, y/o R12, R12' pueden representar juntos O, y donde R4 y R8, o R4 y R8, junto con el átomo al que están unidos, conforman un ciclo de 4, 5, 6 o 7 miembros, saturado o no saturado, que puede contener opcionalmente 1, 2, 3 o 4 heteroátomos seleccionados entre N, S y O; X representa un enlace simple, CH2, O, S o NR; y Q representa (CH2)t-E-(CH2)tR1, -(CH2)t-E-(CH)tRa, (CH2)thalogeno, CHO, (CH2)tSR1, CORa, (CH2)tRa , (CH2)tOCORa, (CH2)tNCOR1, (CH2)tN(R1)2, (CH2)tOR1, (CH2)tOCON(R1)2, (CH2)tOCOOR1, (CH2)tNHCON(R1)2, (CH2)tNHCOOR1, (CH2)tCN o (CH2)tCOOR1; E representa -NR1SO2-, -SO2NR1-, -CONR1-, -NR1CO-, -COO-, -OOC-, -NR1CONR1-, -OCONR1-, -NR1COO-, -CSNR1-, -NR1CS-, -NR1CSNR1-, -SCONR1-, -NR1COS-, -OCSNR1-, NR1CSO-, SCSNR1-, -NR1CSS- o un enlace simple; Ra es un de grupo de formulas (2) a (17), OR, NHR, NR2, NR(CH2)narilo, NR(CH2)nOR, COOR, un radical de N-pirrolidona, OCOR, NR(CH2)nNR2, N[(CH2)nNR2]CO(CH2)narilo, N[(CH2)nNHCOOR]COarilo, R1, N[CH2(CH2)nOR]2, NR(CH2)nNCOOR, X(CH2)nX(CH2)nXR, NR(CH2)nX(CH2)nOH, NR(CH2)nO(CH2)nOH, (CH2)nCOOR, O(CO)NR(CH2)nOR, O(CO)(CH2)nNR2, NR(CH2)nNR2, N[(CH2)nNR2]CO(CH2)narilo, N[(CH2)nXR]CO(CH2)narilo, N[(CH2)nXR]CO(CH2)nheteroarilo, N[(CH2)nNR2]CO(CH2)nheteroarilo, N[(CH2)nNR2]CO(CH2)nR1, N(R)(CH2)nN(R)COOR, XCOO(CH2)nNR2, OSO2A, OSO2CF3, OSO2Ar, OCONR2, OCH2(CH2)nNR2; Z representa CH2, X, CHCONH2, CH(CH2)nNRCOOR, CHNRCOOR, NCO, CH(CH2)nCOOR, NCOOR, CH(CH2)nOH, N(CH2)nOH, CHNH2, CH(CH2)nNR2, CH(CH2)nNR2, C(OH)R, CHNCOR, CH(CH2)narilo, CH(CH2)nheteroarilo, CH(CH2)nR1, N(CH2)nCOOR, CH(CH2)nX(CH2)narilo, CH(CH2)nX(CH2)nheteroarilo, N(CH2)nCONR2, XCONR(CH2)nNR2, N(CH2)nXCOOR, NCO(CH2)narilo, NCO(CH2)nXarilo, NSO2(CH2)narilo, N(CH2)nNRCOOR, C[(CH2)nNR2]CO(CH2)narilo, C[(CH2)nNR2]CO(CH2)nNRarilo, C[(CH2)nNR2]SO2(CH2)narilo, NCO(CH2)nheteroarilo, C[(CH2)nXR]CO(CH2)nXheteroarilo, C[(CH2)nXR]SO2(CH2)nheteroarilo, C[(CH2)nNRCOOR]CO(CH2)nheteroarilo, C[(CH2)nNR2]CO(CH2)nheteroarilo, C[(CH2)nNR2]CO(CH2)nNRheteroarilo, C[(CH2)nNR2]SO2(CH2)nheteroarilo, CHO(CH2)nNR2, CHX(CH2)nNR2, NCO(CH2)nNR2; R6 representa arilo o heteroarilo no sustituido o sustituido con uno o más grupos arilo o heteroarilo, que pueden estar sustituidos con halogeno, NO2, CN, A, OR, OCOR, COR, NR2, CF3, OCF3, OCH(CF3)2, halogeno, NO2, CN, OR, A, -(CY2)n-OR, -OCOR, -(CY2)n-CO2R, -(CY2)n-CN, -NCOR, -COR o -(CY2)n-NR2; R7 representa (C=O)- R, (C=O)-NR2, (C=O)-OR, H o A; k, l y p representan 0, 1 o 2 y preferiblemente 0 o 1, donde k + l + p es distinto de 0 o k + l es distinto de 0; m representa 0, 1 o 2; n representa 0, 1, 2, 3, 4, 5, 6 o 7; s representa 0, 1, 2, 3, 4, 5, o 6; t representa 0, 1, 2, 3, 4, 5, o 6; al igual que los derivados, los solvatos, los tautomeros, las sales y los estereoisomeros aceptables para el uso farmacéutico de éstos, incluyendo sus mezclas en todas las relaciones. Puede emplearse, entre otros, para el tratamiento de tumores.
AR20060102411A 2005-06-13 2006-06-09 Derivados de tetrahidroquinolina AR054282A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005027169A DE102005027169A1 (de) 2005-06-13 2005-06-13 Tetrahydrochinolinderivate

Publications (1)

Publication Number Publication Date
AR054282A1 true AR054282A1 (es) 2007-06-13

Family

ID=36764583

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20060102411A AR054282A1 (es) 2005-06-13 2006-06-09 Derivados de tetrahidroquinolina

Country Status (9)

Country Link
US (1) US8110583B2 (es)
EP (1) EP1891013B1 (es)
JP (1) JP5180071B2 (es)
AR (1) AR054282A1 (es)
AU (1) AU2006257486B2 (es)
CA (1) CA2611892C (es)
DE (1) DE102005027169A1 (es)
ES (1) ES2510473T3 (es)
WO (1) WO2006133805A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005027170A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Substituierte Tetrahydrochinoline
CN101903365B (zh) 2007-10-19 2014-02-05 默沙东公司 用于抑制ksp驱动蛋白活性的螺缩合的1,3,4-噻二唑衍生物
EP2814494B1 (en) 2012-02-14 2019-08-21 Children's Hospital Medical Center Use of small molecule inhibitors targeting the interaction between rac gtpase and p67 (phox)
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
US11672794B2 (en) * 2019-07-17 2023-06-13 Northwestern University Therapeutic targeting of the BAP1 complex in cancer
CN112898202B (zh) * 2021-01-27 2022-11-22 中国科学院上海有机化学研究所 一种杂环基并环丙烷化合物、合成方法
WO2025183207A1 (ja) * 2024-02-28 2025-09-04 国立大学法人京都大学 がん免疫を活性化するスペルミジン誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US20040180889A1 (en) * 2002-03-01 2004-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
DE10236910A1 (de) 2002-08-12 2004-03-11 Grünenthal GmbH Substituierte 1,2,3,4-Tetrahydrochinolinderivate
WO2004072046A2 (en) * 2003-02-12 2004-08-26 Carex S.A. Quinoline derivatives and their use for modulation of lxr activity
SE0301320D0 (sv) * 2003-05-06 2003-05-06 Astrazeneca Ab Positive modulators of nicotinic acetylcholine receptors
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE102005027170A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Substituierte Tetrahydrochinoline

Also Published As

Publication number Publication date
JP2008543796A (ja) 2008-12-04
DE102005027169A1 (de) 2006-12-14
EP1891013A1 (de) 2008-02-27
US8110583B2 (en) 2012-02-07
ES2510473T3 (es) 2014-10-21
US20080221118A1 (en) 2008-09-11
AU2006257486B2 (en) 2011-09-15
EP1891013B1 (de) 2014-07-23
WO2006133805A1 (de) 2006-12-21
CA2611892A1 (en) 2006-12-21
AU2006257486A1 (en) 2006-12-21
JP5180071B2 (ja) 2013-04-10
CA2611892C (en) 2013-08-13

Similar Documents

Publication Publication Date Title
PE20221253A1 (es) Inhibidores de pequenas moleculas de mutante g12c de kras
AR044909A1 (es) Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
AR034390A1 (es) Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
AR119494A1 (es) DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
AR053728A1 (es) Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR069326A1 (es) Derivados bis-(sulfonilamino), proceso de preparacion, composiciones farmaceuticas que los contienen y su uso en terapia.
AR069804A1 (es) Agonistas del receptor glucocorticoide c20- c21 sustituido
AR080878A1 (es) Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos.
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
DOP2007000022A (es) Derivados de n-heteroaril-carboxamidas tricíclicas que contienen un resto bencimidazol, su preparación y su aplicación en terapéutica
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
CY1106398T1 (el) 6,7-διυδρο-5η-πυραζολο[1,2-α]πυραζολ-1-ονες οι οποιες ελεγχουν φλεγμονωδεις κυτοκινες
AR055878A1 (es) Derivados de ciclopropanocarboxamida
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
CO6020016A1 (es) Derivados de 1,2,4,5 tetrahidro-3h-benzapezinas su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
AR054282A1 (es) Derivados de tetrahidroquinolina
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
AR046753A1 (es) Derivados de benzoxazina y usos de los mismos
AR054616A1 (es) Tetrahidroquinolinas sustituidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure